Clinical evaluation of a new Ultra-Rapid Antibiotic Susceptibility Test in Blood Stream Infections

Reference number 2018-03890
Coordinator Astrego Diagnostics AB
Funding from Vinnova SEK 1 671 000
Project duration December 2018 - December 2019
Status Ongoing
Venture Medtech4Health- Collaboration Projects in Medical technology
Call Medtech4Health: Collaboration projects involving medical technology 2018

Purpose and goal

The aim of the project is to evaluate the possibilities and limitations for the use of the Astrego® technology with clinical samples from patients with blood stream infections in central lab settings. The project goal is to develop a user requirement specification for (at least) one product, based on the Astrego’s unique technology, with potential to have a big impact on improving the treatment of blood stream infections and sepsis patients.

Expected results and effects

WHO recently published a Global action plan on antimicrobial resistance, which emphasize the need for rapid, reliable and cost-effective diagnostics to enable improved antibiotic stewardship. In parallel, improved sepsis treatment was appointed a global health priority by WHO. Astrego Diagnostics have a unique technology with a potential to fulfil both these global needs, and at the same time make Astrego a major player on a large and continuously growing global market.

Planned approach and implementation

The project is a collaboration between Astrego Diagnostics and Dept. of Laboratory Medicine at Karolinska Institute. Astrego will provide prototype instruments and disposable cartridges to researchers at Karolinska that have access to a large number of patient samples. The collaboration will enable Astrego to evaluate the suitability of the unique technology for blood stream infections, but also to collect usability feed-back and to document user-requirements for a future product in this field.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.